Patients & Visitors

Contact Information
General Information
(216) 844-8447
(888) 844-8447
11100 Euclid Avenue
Cleveland, OH 44106
Clinical Trial Listing
Trial Name:

GVI 1202
Intro: A Randomized, Phase II Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
Condition:
Description: This study is being done to assess the safety and potential activity of TNFerade biologic in patients randomized to chemoradiation with and without direct intratumoral injection of TNFerade biologic. Patients will be injected with TNFerade biologic once a week for five weeks (weeks 1-5). Radiation and chemotherapy with 5-FU will start on day 1 and continue concomitantly with TNFerade biologic for 5.5 weeks.
Criteria:
  1. Patients must have biopsy proven locally advanced adenocarcinoma of the pancreas assessed to be unresectable
  2. Patients must not have received previous treatment for pancreatic cancer
  3. Patients must have a life expectancy of greater than 3 months
  4. Patients must not have metastatic disease
  5. Patients must have normal bone marrow, liver and kidney function.
Contact: For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422

Participant Confidentiality:

All information regarding participation in Clinical Trials is treated with the utmost confidentiality. University Hospitals Case Medical Center and the Division of Clinical Research recognize and respect the confidentiality of this information. Access to information related to clinical trials and their participants is restricted to authorized clinical trials personnel only.

Back